Company
ArrakisTx
Arrakis set out on a clear mission to open new territories of medicine by creating a pioneering class of genetic medicines: RNA-targeted small molecules (rSMs).
Also known as Arrakis Therapeutics
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Arrakis Therapeutics
- arrakistx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Arrakis has a simple but powerful vision: to extend small-molecule medicines into new realms of RNA biology, unlocking that biology for patients. We are pioneering new territory by discovering small-molecule drug compounds that act directly on RNA, and we call this new drug modality RNA-targeted small molecules (rSMs).
Funding snapshot
- Total raised
- $113MSum of rounds, as of 2026-09-20Source (opens in a new tab)
- Latest round
- Series B, $75M2019-04-18
Funding rounds
- Series B
- $75M2019-04-18, Company stated
- Round, 2019
- $15M2019-04-15, SEC form D sold, 15 investors
- Series A
- $38M2017-02-27, Company stated
- Round, 2017
- $13.2M2017-02-15, SEC form D sold, 8 investors
Loading relationship preview